SCHEMBL10313488

SCHEMBL10313488

Cc1ccc(C2=NC(=O)n3nc(C)c(-c4ccc(C)cc4)c32)cc1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.34
HIF1A Q16665 1/20 0.34
MAPT P10636 3/20 0.33
NPC1 O15118 3/20 0.33
RAB9A P51151 3/20 0.33
SMN1; SMN2 Q16637 3/20 0.33
TP53 P04637 2/20 0.33
MEN1 O00255 2/20 0.33
KMT2A Q03164 2/20 0.33
CYP1A2 P05177 1/20 0.33
CYP3A4 P08684 1/20 0.33
CYP2C9 P11712 1/20 0.33
CYP2C19 P33261 1/20 0.33
POLB P06746 3/20 0.33
RXFP1 Q9HBX9 1/20 0.33
KDM4E B2RXH2 2/20 0.32
USP2 O75604 1/20 0.32
HPGD P15428 2/20 0.32
GRM5 P41594 1/20 0.32
CDK8 P49336 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10275758 0.84 PDE2A (0.40) MAPTNPC1RAB9ASMN1; SMN2KDM4E
SCHEMBL10313530 0.83 CNR1 (0.37) CYP3A4CYP2C9CYP2C19PTGS2
SCHEMBL10313545 0.81 PGR (0.42) ALDH1A1NPC1RAB9ASMN1; SMN2MEN1
SCHEMBL10313601 0.80 ATM (0.40) ALDH1A1HIF1AMAPTNPC1RAB9A
SCHEMBL10275434 0.76 KIF11 (0.46) CYP3A4
SCHEMBL10275596 0.70 PGR (0.38) MAPTNPC1RAB9ASMN1; SMN2CYP1A2
SCHEMBL10313574 0.70 PDE4A (0.38) ALDH1A1NPC1RAB9ASMN1; SMN2MEN1
SCHEMBL10275622 0.70 PDE4A (0.38) MAPTNPC1RAB9ASMN1; SMN2POLB
SCHEMBL10313501 0.67 ALDH1A1 (0.40) ALDH1A1MEN1KMT2ACYP1A2CYP3A4
SCHEMBL31500066 0.67 SMN1; SMN2 (0.59) ALDH1A1HIF1AMAPTNPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120178915-A1 PYRIMIDINE DERIVATIVES AND ANALOGS, PREPARATION METHOD AND USE THEREOF XU LIFENG (US) 2012-07-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120178915-A1 PYRIMIDINE DERIVATIVES AND ANALOGS, PREPARATION METHOD AND USE THEREOF TYMP, TYMS, ADORA3 ALDH1A1 572/4885HIF1A 2245/4885MAPT 750/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.